Please assess the completion status of the following clinical trial:

Trial Title: Prevention of Sepsis-related Organ Dysfunction With Allocetra-OTS

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Suspected, presumed or documented infection from any source.~* Initiation of antibiotics.~* Meets Sepsis 3 criteria: The presence of organ dysfunction as identified by a total SOFA score ≥ 2 points above baseline.~* Adult male or female, age between 18 and 85.~* GCS of \>13 with verbal score of 5.~* Signed written informed consent by the patient.~Exclusion Criteria:~* Participation in an interventional investigational trial within 30 days prior to diagnosis of sepsis.~* Significant trauma requiring hospitalization within 30 days prior to diagnosis of sepsis.~* Surgical intervention or hospitalization within 45 days prior to diagnosis of sepsis.~* Pregnancy or breast-feeding female.~* Progressive or poorly-controlled malignancies or \< 6 month after active treatment for cancer (chemotherapy or irradiation).~* Terminally ill patients defined as patients that prior to the current hospitalization are expected to live \< 6 months (as assessed by the physician responsible for the patient).~* Known active acute or chronic viral infections, e.g. Hepatitis B Virus (HBV) or Hepatitis C Virus (HCV), Human Immunodeficiency Virus (HIV) or other chronic infection.~* Known severe chronic respiratory health problems with severe pulmonary hypertension (≥40 mmHg) or respirator dependency.~* Known active upper gastrointestinal (GI) tract ulceration or hepatic dysfunction including but not limited to: biopsy-proven cirrhosis; portal hypertension; episodes of past upper GI bleeding attributed to portal hypertension; or prior episodes of hepatic failure, encephalopathy, or coma.~* Known New York Heart Association (NYHA) class IV heart failure or unstable angina, ventricular arrhythmias, active ischemic heart disease, or myocardial infarction within six months prior to diagnosis of sepsis.~* Known immunocompromised state or medications known to be immunosuppressive.~* Organ allograft or previous history of stem cell transplantation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Allocetra-OTS (Type: EXPERIMENTAL): Standard of Care (SOC) Drug: One dose Allocetra-OTS 140 140x106 /kg
- Allocetra-OTS Two doses (Type: EXPERIMENTAL): Standard of Care (SOC) Drug: Two doses Allocetra-OTS 140 140x106 /kg

Based on this trial design, predict the completion outcome and termination type (if applicable).